Since launching eight years ago, Causeway Therapeutics has quietly developed a synthetic microRNA molecule it hopes will heal tendon injuries and tested the novel drug in a pair of clinical trials on a slender budget …
What health tech stands to gain as pharma goes DTC
When the Trump administration in September debuted TrumpRx.gov as part of its deal with Pfizer at “most favored nation” prices, my mind immediately turned to


